Citations

Showing 10 of 108083 citations.

Laboratory Services for Managing Thyroid Disease: Different and Common Viewpoints of American Thyroid Association Members and of Members of the Endocrine Division of the American Association for Clinical Chemistry
Grebe, Stefan K., A, on behalf of the American Thyroid, Grebe, Stefan K G, Algeciras‐Schimnich, Alicia

Mayo Clinic

Thyroid | November 8, 2017 | Volume: 27 | Issue: 12 | Pages: 1583-1585

10.1089/thy.2017.0387 | PMID 29113554 Get It

Creating a Full-thickness Choroidal Incision: An Ex Vivo Analysis of Human and Porcine Tissue Contraction Dynamics
Yamada, Norihiro, Choi, Moon Jeong, Olsen, Timothy W. , LoBue, Stephen A

Mayo Clinic

Translational Vision Science & Technology | November 7, 2017 | Volume: 6 | Issue: 6 | Pages: 5

10.1167/tvst.6.6.5 | PMID 29134136 Get It

Factors Influencing Squamous Cell Carcinoma In Situ Recurrence and Implications for Treatment Choice
Matsumoto, Andrew , Schmitt, Adam R., Skelley, Logan M., Baum, Christian L.

Mayo Clinic

Dermatologic Surgery | November 7, 2017 | Volume: 44 | Issue: 5 | Pages: 613-620

10.1097/dss.0000000000001400 | PMID 29112529 Get It

BACKGROUND Numerous treatment modalities have been reported for squamous cell carcinoma in situ (SCCIS). Risk factors for recurrence have not been systematically reviewed. OBJECTIVE To systematically review and summarize the data on risk factors that contribute to recurrence of SCCIS. MATERIALS AND METHODS A PubMed search was completed using the terms “SCCIS,” “Bowen's disease,” “Bowen's disease and recurrence,” and “Bowen's disease and Mohs.” These sources were cross-referenced for the terms “treatment,” “management,” “therapy,” “recurrence,” and “margins.” Studies were selected on the basis of relevance and applicable treatments. RESULTS Immunosuppression was the only variable with a statistically signficant association with progression or recurrence of SCCIS. Although there were no data directly correlating subclinical lateral extension or invasive squamous cell carcinoma within SCCIS with recurrence, evidence supports both of these as common features of SCCIS. Other potential recurrence risk factors for which there are limited supporting data included tumor size, depth of follicular extension, and location. CONCLUSION Immunosuppression was the only risk factor associated with increased risk of tumor recurrence. Subclinical tumor extension and occult invasive squamous cell carcinoma are relatively common features that theoretically could increase recurrence risk. These factors should be considered when deciding upon treatment for SCCIS. Further study is required to quantify variables that influence recurrence and to identify optimal treatment options.
Alcohol and Cancer: A Statement of the American Society of Clinical Oncology
LoConte, Noelle K. , Brewster, Abenaa M. , Kaur, Judith S. , Merrill, Janette K. , Alberg, Anthony J. , LoConte, Noelle

Mayo Clinic

Journal of Clinical Oncology | November 7, 2017 | Volume: 36 | Issue: 1 | Pages: 83-93

10.1200/jco.2017.76.1155 | PMID 29112463 Get It

Alcohol drinking is an established risk factor for several malignancies, and it is a potentially modifiable risk factor for cancer. The Cancer Prevention Committee of the American Society of Clinical Oncology (ASCO) believes that a proactive stance by the Society to minimize excessive exposure to alcohol has important implications for cancer prevention. In addition, the role of alcohol drinking on outcomes in patients with cancer is in its formative stages, and ASCO can play a key role by generating a research agenda. Also, ASCO could provide needed leadership in the cancer community on this issue. In the issuance of this statement, ASCO joins a growing number of international organizations by establishing a platform to support effective public health strategies in this area. The goals of this statement are to: • Promote public education about the risks between alcohol abuse and certain types of cancer; • Support policy efforts to reduce the risk of cancer through evidence-based strategies that prevent excessive use of alcohol; • Provide education to oncology providers about the influence of excessive alcohol use and cancer risks and treatment complications, including clarification of conflicting evidence; and • Identify areas of needed research regarding the relationship between alcohol use and cancer risk and outcomes.
Dysproteinemias and Glomerular Disease
Drosou, Maria Eleni , Nasr, Samih H. , Leung, Nelson

Mayo Clinic

Clinical Journal of the American Society of Nephrology | November 7, 2017 | Volume: 13 | Issue: 1 | Pages: 128-139

10.2215/cjn.00560117 | PMID 29114004 Get It

Dysproteinemia is characterized by the overproduction of an Ig by clonal expansion of cells from the B cell lineage. The resultant monoclonal protein can be composed of the entire Ig or its components. Monoclonal proteins are increasingly recognized as a contributor to kidney disease. They can cause injury in all areas of the kidney, including the glomerular, tubular, and vascular compartments. In the glomerulus, the major mechanism of injury is deposition. Examples of this include Ig amyloidosis, monoclonal Ig deposition disease, immunotactoid glomerulopathy, and cryoglobulinemic GN specifically from types 1 and 2 cryoglobulins. Mechanisms that do not involve Ig deposition include the activation of the complement system, which causes complement deposition in C3 glomerulopathy, and cytokines/growth factors as seen in thrombotic microangiopathy and precipitation, which is involved with cryoglobulinemia. It is important to recognize that nephrotoxic monoclonal proteins can be produced by clones from any of the B cell lineages and that a malignant state is not required for the development of kidney disease. The nephrotoxic clones that do not meet requirement for a malignant condition are now called monoclonal gammopathy of renal significance. Whether it is a malignancy or monoclonal gammopathy of renal significance, preservation of renal function requires substantial reduction of the monoclonal protein. With better understanding of the pathogenesis, clone-directed strategies, such as rituximab against CD20 expressing B cell and bortezomib against plasma cell clones, have been used in the treatment of these diseases. These clone-directed therapies been found to be more effective than immunosuppressive regimens used in nonmonoclonal protein–related kidney diseases.
Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents
Chowdhury, Uttio Roy, Rinkoski, Tommy A. , Bahler, Cindy K., Millar, J. Cameron , Bertrand, Jacques, Holman, Bradley H., Sherwood, Joseph M. , Overby, Darryl R. , Stoltz, Kristen L., Dosa, Peter I. , Fautsch, Michael P. , Roy Chowdhury, Uttio, Bertrand, Jacques A.

Mayo Clinic

Investigative Opthalmology & Visual Science | November 7, 2017 | Volume: 58 | Issue: 13 | Pages: 5731

10.1167/iovs.17-22538 | PMID 29114841 Get It

Porcine to Human Heart Transplantation: Is Clinical Application Now Appropriate?
McGregor, Christopher G.A. , Byrne, Guerard W.

Mayo Clinic

Journal of Immunology Research | November 7, 2017 | Volume: 2017 | Issue: No issue available | Pages: 1-11

10.1155/2017/2534653 | PMID 29238731 Get It

Cardiac xenotransplantation (CXTx) is a promising solution to the chronic shortage of donor hearts. Recent advancements in immune suppression have greatly improved the survival of heterotopic CXTx, now extended beyond 2 years, and life-supporting kidney XTx. Advances in donor genetic modification (B4GALNT2 and CMAH mutations) with proven Gal-deficient donors expressing human complement regulatory protein(s) have also accelerated, reducing donor pig organ antigenicity. These advances can now be combined and tested in life-supporting orthotopic preclinical studies in nonhuman primates and immunologically appropriate models confirming their efficacy and safety for a clinical CXTx program. Preclinical studies should also allow for organ rejection to develop xenospecific assays and therapies to reverse rejection. The complexity of future clinical CXTx presents a substantial and unique set of regulatory challenges which must be addressed to avoid delay; however, dependent on these prospective life-supporting preclinical studies in NHPs, it appears that the scientific path forward is well defined and the era of clinical CXTx is approaching.
A New Era in Critical Care Ultrasound: Professionalization
Brown, Samuel M. , Sekiguchi, Hiroshi , Pinsky, Michael R.

Mayo Clinic

Annals of the American Thoracic Society | November 7, 2017 | Volume: 14 | Issue: 12 | Pages: 1747-1749

10.1513/annalsats.201708-624ps | PMID 29112479 Get It

Impact of Patient Distance From Ventricular Assist Device–Implanting Center on Short- and Long-Term Outcomes
Shah, Palak , Singh, Ramesh , Stulak, John M., Dardas, Todd , Mokadam, Nahush A. , Salerno, Christopher T. , Cowger, Jennifer , Dunlay, Shannon M. , Ravichandran, Ashwin Kumar , Aaronson, Keith D. , Pagani, Francis D. , Shah, Palak

Mayo Clinic

ASAIO Journal | November 7, 2017 | Volume: 64 | Issue: 6 | Pages: 721-726

10.1097/mat.0000000000000717 | PMID 29117042 Get It

Highly specialized left ventricular assist device care is not readily available in many areas, potentially limiting access to therapy. This retrospective analysis examines the relationship of outcomes by patient distance from implanting left ventricular assist device center within the Mechanical Circulatory Support Research Network. Zip codes were used to calculate patient distance, with the primary outcome of interest being 3-year survival by distance from the surgical center. Secondary outcomes included 90-day survival and incident event rates for the following: gastrointestinal bleeding, infection, cerebral event, and pump thrombosis. Across the four centers, there were 1184 patients supported for a median of 486 days. Overall survival was 91 ± 0.8% at 90 days and 61 ± 1.9% at 3 years, with worse 3-year survival in those living >90 vs . ≤90 miles from the ventricular assist device implant center (55 ± 3.0% vs . 64 ± 2.5, p = 0.019). Patients living >90 miles from an implant center were older, more likely to be implanted for destination therapy support, had a prior sternotomy, and had worse renal function than those living closer ( p <0.05 for all). After adjusting for these factors, albumin and center of implant, the hazard ratio did not reach statistical significance (hazard ratio = 1.2; p = 0.14). Except for gastrointestinal bleeding, the event rates for the secondary outcomes were higher for those living closer to the implanting center. Protocols should be designed for more frequent follow-up and increased shared care opportunities to ensure optimal outcomes are achieved in distant patients.
A Rose by Other Names: Some General Musings on Lawrence and Colleagues’ Hidden Curriculum Scoping Review
Hafferty, Frederic W. , Martimianakis, Maria Athina

Mayo Clinic

Academic Medicine | November 7, 2017 | Volume: 93 | Issue: 4 | Pages: 526-531

10.1097/acm.0000000000002025 | PMID 29116982 Get It

In this Commentary, the authors explore the scoping review by Lawrence and colleagues by challenging their conclusion that with over 25 years’ worth of “ambiguous and seemingly ubiquitous use” of the hidden curriculum construct in health professions education scholarship, it is time to either move to a more uniform definitional foundation or abandon the term altogether. The Commentary authors counter these remedial propositions by foregrounding the importance of theoretical diversity and the conceptual richness afforded when the hidden curriculum construct is used as an entry point for studying the interstitial space between the formal and a range of other-than-formal domains of learning. They document how tightly delimited scoping strategies fail to capture the wealth of educational scholarship that operates within a hidden curriculum framework, including “hidden” hidden curriculum articles, studies that employ alternative constructs, and investigations that target important tacit sociocultural influences on learners and faculty without formally deploying the term. They offer examples of how the hidden curriculum construct, while undergoing significant transformation in its application within the field of health professions education, has created the conceptual foundation for the application of a number of critical perspectives that make visible the field’s political investments in particular forms of knowing and associated practices. Finally, the Commentary authors invite readers to consider the methodological promise afforded by conceptual heterogeneity, particularly strands of scholarship that resituate the hidden curriculum concept within the magically expansive dance of social relationships, social learning, and social life that form the learning environments of health professions education.